Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy of Large Nodular Goiters Facilitates Tracheal Decompression and Improves Inspiration

Author:

Bonnema Steen J.1,Nielsen Viveque E.1,Boel-Jørgensen Henrik2,Grupe Peter2,Andersen Peter B.3,Bastholt Lars4,Hegedüs Laszlo1

Affiliation:

1. Departments of Endocrinology and Metabolism (S.J.B., V.E.N., L.H.), Odense University Hospital, DK-5000 Odense C, Denmark

2. Nuclear Medicine (H.B-J., P.G.), Odense University Hospital, DK-5000 Odense C, Denmark

3. Radiology (P.B.A.), Odense University Hospital, DK-5000 Odense C, Denmark

4. Oncology (L.B.), Odense University Hospital, DK-5000 Odense C, Denmark

Abstract

Introduction: The impact on tracheal anatomy and respiratory function of recombinant human (rh)TSH-stimulated 131I therapy in patients with goiter is not clarified. Methods: In a double-blinded design, patients (age 37–87 yr) with a large multinodular goiter (range, 99–440 ml) were randomized to placebo (n = 15) or 0.3 mg rhTSH (n = 14) 24 h before 131I therapy. The smallest cross-sectional area of the trachea (SCAT; assessed by magnetic resonance imaging) and the pulmonary function were determined before, 1 wk, and 12 months after therapy. Results: Data on goiter reduction have been reported previously. In the placebo group, no significant changes in the lung function or SCAT were found throughout the study. In the rhTSH group, a slight decrease was observed in the forced vital capacity 1 wk after therapy, whereas the mean individual change in SCAT was significantly increased by 10.5% (95% confidence interval = 0.9–20.0%). A further increase in SCAT to 117 ± 36 mm2 (P = 0.005 compared with 92 ± 38 mm2 at baseline) was seen at 12 months, corresponding to a mean of 31.4% (95% confidence interval = 16.0–46.8%). The expiratory parameters did not change significantly, whereas forced inspiratory flow at 50% of the vital capacity (FIF50%) increased from initially 3.34 ± 1.33 liters/sec to ultimately 4.23 ± 1.88 liters/sec (P = 0.015) in the rhTSH group, corresponding to a median increase of 24.6%. By 12 months, the relative improvements in FIF50% and in SCAT were inversely correlated to the respective baseline values (FIF50%: r = −0.47, P = 0.012; SCAT: r = −0.57, P = 0.001). Conclusion: On average, neither compression of the trachea nor deterioration of the pulmonary function was observed in the acute phase after rhTSH-augmented 131I therapy. In the long term, tracheal compression is diminished, and the inspiratory capacity improved, compared with 131I therapy alone.

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. The EANM guideline on radioiodine therapy of benign thyroid disease;European Journal of Nuclear Medicine and Molecular Imaging;2023-07-03

2. 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management;European Thyroid Journal;2023-06-23

3. Non-Toxic Multinodular Goiter: From Etiopathogenesis to Treatment;SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital;2022

4. Recombinant human thyrotropin (rhTSH)-aided radioiodine treatment for non-toxic multinodular goitre;Cochrane Database of Systematic Reviews;2021-12-28

5. Mechanistic reasoning and the problem of masking;Synthese;2021-02-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3